Hansoh Pharma Reports H1 2025 Revenue of RMB 7.434 Billion, Up 14.3% YoY, with Innovative Drugs Accounting for 82.7% of Total Revenue

Hansoh Pharma Announces Financial Results: Achieved Total Revenue of Approximately RMB 74.34 Billion in the First Half of 2025, Representing a Year-on-Year Increase of About 14.3%; Profit Reached Approximately RMB 31.35 Billion, Up by Around 15.0% Year-on-Year. Basic Earnings Per Share Were Approximately RMB 0.53, Reflecting a Year-on-Year Growth of About 14.8%, with an Interim Dividend of HKD 23.16 Cents Per Share, Demonstrating Strong Profitability and Generous Returns to Shareholders.

Thanks to the continuous growth of innovative products and the steady progress of global collaborations, in the first half of 2025, the sales revenue of Hansoh Pharma's innovative drugs and collaborative products reached approximately RMB 6.145 billion, representing a year-on-year increase of about 22.1%, and accounting for 82.7% of total revenue.

According to the financial report, the net cash inflow from operating activities in the first half of 2025 was RMB 3.605 billion, with cash and bank deposits amounting to RMB 27.104 billion as of June 30, 2025. The robust financial performance and strong cash flow lay a solid foundation for supporting the company's continuous innovation and R&D investment in the future.